Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study

BMJ. 2011 Jul 28:343:d4044. doi: 10.1136/bmj.d4044.

Abstract

Objective: To estimate the potential cost effectiveness of a population-wide risk factor reduction programme aimed at preventing cardiovascular disease.

Design: Economic modelling analysis.

Setting: England and Wales. Population Entire population. Model Spreadsheet model to quantify the reduction in cardiovascular disease over a decade, assuming the benefits apply consistently for men and women across age and risk groups.

Main outcome measures: Cardiovascular events avoided, quality adjusted life years gained, and savings in healthcare costs for a given effectiveness; estimates of how much it would be worth spending to achieve a specific outcome.

Results: A programme across the entire population of England and Wales (about 50 million people) that reduced cardiovascular events by just 1% would result in savings to the health service worth at least £30m (€34m; $48m) a year compared with no additional intervention. Reducing mean cholesterol concentrations or blood pressure levels in the population by 5% (as already achieved by similar interventions in some other countries) would result in annual savings worth at least £80m to £100m. Legislation or other measures to reduce dietary salt intake by 3 g/day (current mean intake approximately 8.5 g/day) would prevent approximately 30,000 cardiovascular events, with savings worth at least £40m a year. Legislation to reduce intake of industrial trans fatty acid by approximately 0.5% of total energy content might gain around 570,000 life years and generate NHS savings worth at least £230m a year.

Conclusions: Any intervention that achieved even a modest population-wide reduction in any major cardiovascular risk factor would produce a net cost saving to the NHS, as well as improving health. Given the conservative assumptions used in this model, the true benefits would probably be greater.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Cardiovascular Diseases / economics
  • Cardiovascular Diseases / prevention & control*
  • Cost Savings
  • Cost of Illness
  • Cost-Benefit Analysis
  • Dietary Fats / administration & dosage
  • England
  • Female
  • Food Industry / legislation & jurisprudence
  • Health Policy
  • Humans
  • Hypercholesterolemia / economics
  • Hypercholesterolemia / prevention & control
  • Hypertension / economics
  • Hypertension / prevention & control
  • Legislation, Food
  • Male
  • Middle Aged
  • Prognosis
  • Quality-Adjusted Life Years
  • Risk Factors
  • Sodium Chloride, Dietary / administration & dosage
  • State Medicine / economics
  • Wales

Substances

  • Dietary Fats
  • Sodium Chloride, Dietary